Making choices at menopause.


Journal

Australian journal of general practice
ISSN: 2208-7958
Titre abrégé: Aust J Gen Pract
Pays: Australia
ID NLM: 101718099

Informations de publication

Date de publication:
07 2019
Historique:
entrez: 1 7 2019
pubmed: 2 7 2019
medline: 25 8 2020
Statut: ppublish

Résumé

Menopause is a time of change in women's lives and an opportunity for health promotion. Women can present with a range of symptoms and concerns. The aim of this article is to review the key components of the assessment of women who are perimenopausal or menopausal, and to discuss the benefits and risks of hormonal and non-hormonal treatments, thereby assisting clinicians to appropriately manage these women. The majority of women who are symptomatic can be offered menopausal hormone therapy (MHT). To ensure women can make an informed choice about whether to use MHT, it is important for them to receive balanced and accurate information about the benefits and risks. For women with contraindications to MHT, or women who prefer not to use hormones, non-hormonal and complementary options may be considered. New non-hormonal options are likely to be available in the future.

Sections du résumé

BACKGROUND
Menopause is a time of change in women's lives and an opportunity for health promotion. Women can present with a range of symptoms and concerns.
OBJECTIVE
The aim of this article is to review the key components of the assessment of women who are perimenopausal or menopausal, and to discuss the benefits and risks of hormonal and non-hormonal treatments, thereby assisting clinicians to appropriately manage these women.
DISCUSSION
The majority of women who are symptomatic can be offered menopausal hormone therapy (MHT). To ensure women can make an informed choice about whether to use MHT, it is important for them to receive balanced and accurate information about the benefits and risks. For women with contraindications to MHT, or women who prefer not to use hormones, non-hormonal and complementary options may be considered. New non-hormonal options are likely to be available in the future.

Identifiants

pubmed: 31256513
doi: 10.31128/AJGP-02-19-4851
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

457-462

Auteurs

Karen Magraith (K)

BMBS, FRACGP, Board Member, Australasian Menopause Society, Vic; General Practitioner, Tas. karens.magraith@bigpond.com.

Bronwyn Stuckey (B)

BA, MBBS, FRACP, Director, Keogh Institute for Medical Research, WA; Clinical Professor, School of Medicine and Pharmacology, University of Western Australia, WA; Consultant, Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, WA; Board Member, Australasian Menopause Society, Vic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH